[go: up one dir, main page]

GT200900241A - Compuestos amino-5-[-4-(difluorometoxi )fenil sustituido]-5-fenilimidazolona como inhidibidores de beta secretasa - Google Patents

Compuestos amino-5-[-4-(difluorometoxi )fenil sustituido]-5-fenilimidazolona como inhidibidores de beta secretasa

Info

Publication number
GT200900241A
GT200900241A GT200900241A GT200900241A GT200900241A GT 200900241 A GT200900241 A GT 200900241A GT 200900241 A GT200900241 A GT 200900241A GT 200900241 A GT200900241 A GT 200900241A GT 200900241 A GT200900241 A GT 200900241A
Authority
GT
Guatemala
Prior art keywords
beta
inhidibers
difluorometoxi
amino
phenylimidazolone
Prior art date
Application number
GT200900241A
Other languages
English (en)
Inventor
Michael Sotirios Malamas
Albert Jean Robichaud
Alexander Michael Porte
William Ronald Solvibile
Koi Michele Morris
Schuyler Adam Antane
Ji-In Kim
Robert Emmett Mcdevitt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900241A publication Critical patent/GT200900241A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI )FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIDIBIDORES DE BETA SECRETASA POR LO QUE SON DE UTILIDAD EN CUADROS O TRASTORNOS ASOCIADOS CON DEPOSITOS BETA-AMILOIDES Y OVILLOS NEUROFIBRILARES, QUE INCLUYEN EL ALZHEIMER, TRISOMIA 21, HEMORRAGIA CEREBRAL Y OTROS TRASTORNOS NEURODEGENERATIVOS.
GT200900241A 2007-03-20 2009-09-10 Compuestos amino-5-[-4-(difluorometoxi )fenil sustituido]-5-fenilimidazolona como inhidibidores de beta secretasa GT200900241A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91908707P 2007-03-20 2007-03-20

Publications (1)

Publication Number Publication Date
GT200900241A true GT200900241A (es) 2010-05-07

Family

ID=39564223

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900241A GT200900241A (es) 2007-03-20 2009-09-10 Compuestos amino-5-[-4-(difluorometoxi )fenil sustituido]-5-fenilimidazolona como inhidibidores de beta secretasa

Country Status (24)

Country Link
US (1) US20090042964A1 (es)
EP (1) EP2137161A1 (es)
JP (1) JP2010522235A (es)
KR (1) KR20100015376A (es)
CN (1) CN101641335A (es)
AR (1) AR065811A1 (es)
AU (1) AU2008229327A1 (es)
BR (1) BRPI0808944A2 (es)
CA (1) CA2681243A1 (es)
CL (1) CL2008000784A1 (es)
CO (1) CO6140056A2 (es)
CR (1) CR11020A (es)
EC (1) ECSP099639A (es)
GT (1) GT200900241A (es)
IL (1) IL200961A0 (es)
MX (1) MX2009009699A (es)
NI (1) NI200900164A (es)
PA (1) PA8772701A1 (es)
PE (1) PE20090160A1 (es)
RU (1) RU2009133807A (es)
SV (1) SV2009003373A (es)
TW (1) TW200845965A (es)
WO (1) WO2008115552A1 (es)
ZA (1) ZA200906542B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW201004961A (en) 2005-06-14 2010-02-01 Schering Corp Aspartyl protease inhibitors
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EP2184276A1 (en) * 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
KR20120001756A (ko) 2009-03-13 2012-01-04 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ベータセクレターゼインヒビター
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
EP2900650A1 (en) 2012-09-28 2015-08-05 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
DK2956443T3 (da) * 2013-02-12 2020-01-20 Buck Inst Res Aging Hydantoiner som modulatorer af BACE-medieret APP-forarbejdning
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
CA3096505A1 (en) 2018-04-23 2019-10-31 Merck Sharp & Dohme Corp. Novel process for synthesis of a phenoxy diaminopyrimidine compound
CN109289696B (zh) * 2018-10-29 2022-03-22 天津先光化工有限公司 一种咪唑啉两性表面活性剂的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45198B1 (en) * 1976-06-05 1982-07-14 Wyeth John & Brother Ltd Guanidine derivatives
GB1588096A (en) * 1978-05-20 1981-04-15 Wyeth & Bros Ltd John Pyrrole derivatives
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
DE10046993A1 (de) * 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
WO2003094854A2 (en) * 2002-05-07 2003-11-20 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
ES2332659T3 (es) * 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
WO2006009655A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
EP2264036A1 (en) * 2005-01-14 2010-12-22 Wyeth LLC (Formerly Known As Wyeth) Amino-imidazolones for the inhibition of beta-secretase
BRPI0607094A2 (pt) * 2005-02-01 2009-08-04 Wyeth Corp composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica
AU2006214627A1 (en) * 2005-02-14 2006-08-24 Wyeth Azolylacylguanidines as beta-secretase inhibitors
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
WO2006088694A1 (en) * 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
BRPI0613578A2 (pt) * 2005-06-30 2012-01-17 Wyeth Corp composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
RU2008106936A (ru) * 2005-09-26 2009-11-10 Вайет (Us) Соединения амино-5-[4-(дифторметокси)фенил]-5-фенилимидазолона для ингибирования бета-секретазы
CN101360737A (zh) * 2005-12-19 2009-02-04 惠氏公司 2-氨基-5-哌啶咪唑酮化合物和其用于β分泌酶调节的用途
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
WO2008036196A2 (en) * 2006-09-21 2008-03-27 Wyeth Indolylalkylpyridin-2-amines for the inhibition of beta-secretase

Also Published As

Publication number Publication date
RU2009133807A (ru) 2011-04-27
CR11020A (es) 2009-10-06
CL2008000784A1 (es) 2008-05-30
NI200900164A (es) 2010-07-29
CN101641335A (zh) 2010-02-03
ZA200906542B (en) 2010-06-30
WO2008115552A1 (en) 2008-09-25
PE20090160A1 (es) 2009-02-11
TW200845965A (en) 2008-12-01
SV2009003373A (es) 2010-08-10
AU2008229327A8 (en) 2009-10-15
EP2137161A1 (en) 2009-12-30
BRPI0808944A2 (pt) 2014-09-02
AU2008229327A1 (en) 2008-09-25
US20090042964A1 (en) 2009-02-12
CA2681243A1 (en) 2008-09-25
IL200961A0 (en) 2010-05-17
AR065811A1 (es) 2009-07-01
PA8772701A1 (es) 2008-11-19
MX2009009699A (es) 2009-09-24
CO6140056A2 (es) 2010-03-19
ECSP099639A (es) 2009-10-30
JP2010522235A (ja) 2010-07-01
KR20100015376A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
GT200900241A (es) Compuestos amino-5-[-4-(difluorometoxi )fenil sustituido]-5-fenilimidazolona como inhidibidores de beta secretasa
CO7111287A2 (es) Composiciones plaguicidas y procesos relacionados
ATE534717T1 (de) Anzeigesystem
GT201400168A (es) Agonistas de mglu 2/3
TH1701005902A (th) องค์ประกอบต้านจุลชีพ
TH701000798A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701001063A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701001480A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701001838A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701002130A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701002266A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701002817A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701003380A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701003454A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701004739A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701005247A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701005335A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH703000847A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
UA17253S (uk) Автобус міжміський другого класу баз-а079.14
UA17255S (uk) Автобус міжміський другого класу баз-а079.19
TH701000168A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701005877A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH1103000976A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH1403000502A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH701000015A (th) สิทธิบัตรยังไม่ประกาศโฆษณา